News

MedTech Category: Meet the EIT Health Catapult 2021 regional finalists: Adiposs, Terapet, ThinkSono and Thericon

Twelve finalists were chosen for this year’s D.A.CH. Regional Selection of the EIT Health Catapult. Here are the shortlisted candidates from the MedTech Category: Adiposs, Terapet, ThinkSono and Thericon.

On 11 May 2021, we are hosting the D.A.CH. Regional Selection of EIT Health Catapult and this year the exciting pitch competition will include 12 promising startups from Europe. Meet the four MedTech teams and learn more about their projects:

 

Adiposs

Product/service idea in 50 words or less:
Every year 3 million patients die because of body wasting. Adiposs has developed a game-changing product called ImageBAT that can detect body wasting before irreversible weight loss, and when treatments are effective. Adiposs makes body wasting visible and enables early treatment for millions of patients, giving them better and longer lives.

 

Origins of the idea:
ImageBAT technology stems from the multidisciplinary brown adipose tissue project started at the University of Geneva in 2014. Andrej Babic, CEO and co-founder of Adiposs is one of the initial co-inventors of the technology and has enabled its translation into a game-changing product for body wasting syndrome in cancer and chronic disease patients.

Key differentiated product features:
ImageBAT is a first-in-class medical imaging agent for the non-invasive detection of brown fat. ImageBAT is a game-changer able to detect early qualitative changes in body fat before weight loss. It enables early diagnosis of body wasting by a CT scan available in every hospital worldwide. ImageBAT is a patient-friendly oral product. It is an add-on product to the fast and pain-free CT scan that patients have as a part of their standard disease follow-up.

Reasons for applying to EIT Health Catapult:
EIT Catapult will be the turbo-springboard for Adiposs towards becoming a great company with a game-changing technology that can be commercialized and used worldwide.

Future plans & ambitions. What’s next?
Adiposs will start the first clinical trial in healthy volunteers and patients this year and develop a clinical pipeline of ImageBAT products for several indications (namely cancer and COPD). We aim to achieve regulatory approval and first sales in the EU and US in 2024.

 

Terapet

Product/service idea in 50 words or less:
Our product is a novel medical device, which enables medical doctors for the first time to monitor proton dose inside the patients during treatment: in-vivo, non-invasive, in 3D and real-time.

 

Origins of the idea:
The idea for this project was born in 2018 from Marcus, our CTO, also a CERN physicist who’s the main responsible for the design of a proton therapy facility in Austria (MedAustron), and the main responsible for two light-based detectors in the LHC (Large Hadron Collider) at CERN.

Key differentiated product features:
Our product is a novel medical device protected by three patents, which enables medical doctors for the first time to monitor proton dose inside the patients during treatment: in-vivo, non-invasive, in 3D and real-time. The technology is complex and requires the knowledge and know-how from more than 30 years of state-of-the-art detector development at CERN.

Reasons for applying to EIT Health Catapult:
We would like to benefit from the opportunity of the EIT health Catapult to broaden the visibility within the European startup ecosystem as well as gain contacts with new investors to boost our upcoming Series A round.

Future plans & ambitions. What’s next?
For the coming two years, Terapet together with our partners, CERN, Karolinska and Skandion, will build the first full-scale prototype ready for clinical validation toward CE-certification. By the end of 2021, Terapet will complete a Series A round of 5 MCHF in order to complete the team up to 18 FTE, hire a salesperson, set up the first manufacturing partner. By the end of 2024, Terapet will complete a Series B round of 10 MCHF in order to complete CE certification and start production and non-partner sales. Our long-term vision is to see our device being a standard tool in every proton therapy facility. We are here to bring proton therapy to the next level, and make sure that every patient receives the right dose, every time.

 

Thericon

Product/service idea in 50 words or less:
Thericon plans to develop a new generation of endoscopy cameras. Thericon’s unique approach to multispectral imaging provides, for the first time, multi-parametric images that visualise anatomical, functional and pathological features of tissue simultaneously, in real-time, and using a single device.

Origins of the idea:
The idea of real-time multispectral imaging (rMSI) came in 2013, when Roger Tsien, Nobel Laureate in Chemistry, spread his idea of peptide-based fluorescence labelling of various types of tissues to aid surgeons visualize functional anatomical and pathological features of tissue and guide their surgeries. At the time, there were no available technologies to achieve the simultaneous imaging of all this information, and we invented and applied for patents on rMSI, which is a technology platform that addresses the needs of multiple contrast minimally invasive surgery.

Key differentiated product features:
Thericon’s devices differentiate themselves from existing products and technologies by introducing novel product features and advantages, including real-time functional and anatomical endoscopic imaging, and providing an unprecedented wealth of diagnostic information during surgery. A single Thericon imaging platform covers all the endoscopic imaging needs of a hospital, eliminating the need for multiple systems, each dedicated to a particular surgical application. Thericon’s devices address multiple clinical applications and serve as enablers for advances in computer-aided decision support systems and surgeries with multiple contrast agents (e.g. to highlight nerves and blood vessels in different colours). Considering their USPs, Thericon’s devices have the potential to become the new gold standard for endoscopic visualization in multiple surgical specialities.

Reasons for applying to EIT Health Catapult:
After an intensive proof of concept/feasibility period, Thericon has spun off from University Heidelberg and Fraunhofer Institute and is proving the value of its business case. Thericon’s current efforts focus on the consolidation of its business value and fundraising. EIT Health Catapult program fits exactly to Thericon’s current business stage. It is expected that Thericon will benefit in terms of interacting with stakeholders and advisors, training in business development, pitching to a wide range of investors, and gaining visibility. We learned about EHC from advertisements in social media, and we have verified the fit after discussing it with the national CLC.

Future plans & ambitions. What’s next?
Thericon is fundraising for the seed round to finance the development and certification of the first rMSI rigid endoscope camera. Our future plans include international launch and the integration of rMSI technology into flexible and 3D endoscopes.

 

ThinkSono

Product/service idea in 50 words or less:
AutoDVT is the world’s first software to detect deep vein thrombosis (DVT). It is an app (iOS/Android) that connects to widely available handheld ultrasound devices. AutoDVT enables a nurse, junior doctors and emergency doctor to detect DVT in as little as 5 minutes. This saves costs and improves outcomes.

Origins of the idea:
AutoDVT was conceived while the founders of ThinkSono were participating in a startup accelerator called Entrepreneur First in 2016. They found out about DVT and how big of an issue it is and decided to solve it. They received support from world-class clinicians, engineers and investors.

Key differentiated product features:
AutoDVT is the only software that enables a non-specialist (e.g nurse) to detect DVT at the point of care.

Reasons for applying to EIT Health Catapult:
In order to obtain support and investment.

Future plans & ambitions. What’s next?
Running clinical trials and commercialisation of the technology.

 

Good luck to the teams!